Through CTD analysis, we found that the small molecule compounds involved in HBG1/HBD contain an important component of edoxaban (methyl methanesulfonate), and then concluded that edoxaban can effectively reduce lipids and fibrosis through HBG1/HBD biomarkers to prevent AF and coagulation. The gene discussed is HBG1; the disease is atrial fibrillation.